Cargando…

The Need for Restructuring the Disordered Science of Amorphous Drug Formulations

The alarming numbers of poorly soluble discovery compounds have centered the efforts towards finding strategies to improve the solubility. One of the attractive approaches to enhance solubility is via amorphization despite the stability issue associated with it. Although the number of amorphous-base...

Descripción completa

Detalles Bibliográficos
Autores principales: Edueng, Khadijah, Mahlin, Denny, Bergström, Christel A. S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5533858/
https://www.ncbi.nlm.nih.gov/pubmed/28523384
http://dx.doi.org/10.1007/s11095-017-2174-7
_version_ 1783253685314256896
author Edueng, Khadijah
Mahlin, Denny
Bergström, Christel A. S.
author_facet Edueng, Khadijah
Mahlin, Denny
Bergström, Christel A. S.
author_sort Edueng, Khadijah
collection PubMed
description The alarming numbers of poorly soluble discovery compounds have centered the efforts towards finding strategies to improve the solubility. One of the attractive approaches to enhance solubility is via amorphization despite the stability issue associated with it. Although the number of amorphous-based research reports has increased tremendously after year 2000, little is known on the current research practice in designing amorphous formulation and how it has changed after the concept of solid dispersion was first introduced decades ago. In this review we try to answer the following questions: What model compounds and excipients have been used in amorphous-based research? How were these two components selected and prepared? What methods have been used to assess the performance of amorphous formulation? What methodology have evolved and/or been standardized since amorphous-based formulation was first introduced and to what extent have we embraced on new methods? Is the extent of research mirrored in the number of marketed amorphous drug products? We have summarized the history and evolution of amorphous formulation and discuss the current status of amorphous formulation-related research practice. We also explore the potential uses of old experimental methods and how they can be used in tandem with computational tools in designing amorphous formulation more efficiently than the traditional trial-and-error approach.
format Online
Article
Text
id pubmed-5533858
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Springer US
record_format MEDLINE/PubMed
spelling pubmed-55338582017-08-11 The Need for Restructuring the Disordered Science of Amorphous Drug Formulations Edueng, Khadijah Mahlin, Denny Bergström, Christel A. S. Pharm Res Expert Review The alarming numbers of poorly soluble discovery compounds have centered the efforts towards finding strategies to improve the solubility. One of the attractive approaches to enhance solubility is via amorphization despite the stability issue associated with it. Although the number of amorphous-based research reports has increased tremendously after year 2000, little is known on the current research practice in designing amorphous formulation and how it has changed after the concept of solid dispersion was first introduced decades ago. In this review we try to answer the following questions: What model compounds and excipients have been used in amorphous-based research? How were these two components selected and prepared? What methods have been used to assess the performance of amorphous formulation? What methodology have evolved and/or been standardized since amorphous-based formulation was first introduced and to what extent have we embraced on new methods? Is the extent of research mirrored in the number of marketed amorphous drug products? We have summarized the history and evolution of amorphous formulation and discuss the current status of amorphous formulation-related research practice. We also explore the potential uses of old experimental methods and how they can be used in tandem with computational tools in designing amorphous formulation more efficiently than the traditional trial-and-error approach. Springer US 2017-05-18 2017 /pmc/articles/PMC5533858/ /pubmed/28523384 http://dx.doi.org/10.1007/s11095-017-2174-7 Text en © The Author(s) 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Expert Review
Edueng, Khadijah
Mahlin, Denny
Bergström, Christel A. S.
The Need for Restructuring the Disordered Science of Amorphous Drug Formulations
title The Need for Restructuring the Disordered Science of Amorphous Drug Formulations
title_full The Need for Restructuring the Disordered Science of Amorphous Drug Formulations
title_fullStr The Need for Restructuring the Disordered Science of Amorphous Drug Formulations
title_full_unstemmed The Need for Restructuring the Disordered Science of Amorphous Drug Formulations
title_short The Need for Restructuring the Disordered Science of Amorphous Drug Formulations
title_sort need for restructuring the disordered science of amorphous drug formulations
topic Expert Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5533858/
https://www.ncbi.nlm.nih.gov/pubmed/28523384
http://dx.doi.org/10.1007/s11095-017-2174-7
work_keys_str_mv AT eduengkhadijah theneedforrestructuringthedisorderedscienceofamorphousdrugformulations
AT mahlindenny theneedforrestructuringthedisorderedscienceofamorphousdrugformulations
AT bergstromchristelas theneedforrestructuringthedisorderedscienceofamorphousdrugformulations
AT eduengkhadijah needforrestructuringthedisorderedscienceofamorphousdrugformulations
AT mahlindenny needforrestructuringthedisorderedscienceofamorphousdrugformulations
AT bergstromchristelas needforrestructuringthedisorderedscienceofamorphousdrugformulations